Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia

Joanna M Rhodes,1 Anthony R Mato2 1CLL Research and Treatment Center, Northwell Health Cancer Institute, Barbara and Donald Zucker School of Medicine at Northwell/Hofstra, New Hyde Park, NY, USA; 2Chronic Lymphocytic Leukemia Program, Memorial Sloan Kettering Cancer Center, New York, NY, USACorrespo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rhodes JM (Author), Mato AR (Author)
Formato: Livro
Publicado em: Dove Medical Press, 2021-03-01T00:00:00Z.
Assuntos:
Acesso em linha:Connect to this object online.
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!